Share on StockTwits

Tissue Regenix Group PLC (LON:TRX)‘s stock had its “buy” rating restated by investment analysts at Panmure Gordon in a note issued to investors on Wednesday. They currently have a GBX 29 ($0.49) target price on the stock. Panmure Gordon’s target price suggests a potential upside of 7.41% from the company’s current price.

Shares of Tissue Regenix Group PLC (LON:TRX) traded down 1.82% during mid-day trading on Wednesday, hitting GBX 27.00. The stock had a trading volume of 283,159 shares. Tissue Regenix Group PLC has a 52-week low of GBX 18.52 and a 52-week high of GBX 30.485. The stock has a 50-day moving average of GBX 0. and a 200-day moving average of GBX 0..

Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Tissue Regenix Group PLC in a research note on Wednesday. They now have a GBX 29 ($0.49) price target on the stock.

Tissue Regenix Group plc, is a United Kingdom-based holding company. It is a regenerative medical devices company, which uses animal or human tissue to replace damaged or worn out parts of the human body.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.